Novo Nordisk

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. 

CEO
Maziar Mike Doustdar
CEOMaziar Mike Doustdar
Employees
68,794
Employees68,794
Headquarters
Bagsværd, Capital Region
HeadquartersBagsværd, Capital Region
Founded
1923
Founded1923
Employees
68,794
Employees68,794

NVO Key Statistics

Market cap
204.59B
Market cap204.59B
Price-Earnings ratio
10.69
Price-Earnings ratio10.69
Dividend yield
2.70%
Dividend yield2.70%
Average volume
12.10M
Average volume12.10M
High today
$46.15
High today$46.15
Low today
$45.15
Low today$45.15
Open price
$45.49
Open price$45.49
Volume
10.99M
Volume10.99M
52 Week high
$81.44
52 Week high$81.44
52 Week low
$35.12
52 Week low$35.12

NVO News

Simply Wall St 5h
Assessing Novo Nordisk Valuation After Mixed Returns And Earnings Snapshot

Advertisement Why Novo Nordisk (NYSE:NVO) Is Back On Investors’ Radar Novo Nordisk (NYSE:NVO) has drawn attention recently after its stock moved alongside rep...

Assessing Novo Nordisk Valuation After Mixed Returns And Earnings Snapshot
The Motley Fool 6h
Lilly's New Drug Just Delivered the Largest Weight Loss Ever Seen in a Clinical Trial -- Here's What It Means for Investors

The big news in the GLP-1 weight loss drug space right now is the introduction of pills. That seems to have broadened the appeal of GLP-1s, as many consumers si...

Lilly's New Drug Just Delivered the Largest Weight Loss Ever Seen in a Clinical Trial -- Here's What It Means for Investors
The Motley Fool 11h
Stock Split Watch: Is Eli Lilly Next?

Eli Lilly (LLY 1.87%) may not immediately come to mind when you think of growth stocks. Instead, you might think of technology or even consumer-oriented players...

Stock Split Watch: Is Eli Lilly Next?

Analyst ratings

54%

of 37 ratings
Buy
37.8%
Hold
54.1%
Sell
8.1%

More NVO News

TipRanks 1d
Novo Nordisk’s CagriSema Trial Puts Next-Generation Obesity Strategy in Focus

Novo Nordisk (NVO) announced an update on their ongoing clinical study. Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings...

MarketWatch 2d
Lilly’s GLP-1 medications will soon be covered by CVS, potentially opening access for millions of Americans

Eli Lilly’s stock is on track for a record close after the drugmaker disclosed that one of the nation’s most powerful pharmacy-benefit managers will start cover...

Lilly’s GLP-1 medications will soon be covered by CVS, potentially opening access for millions of Americans
Nasdaq 2d
Contrarian Opinion: Novo Nordisk Is A Better Buy Than Eli Lilly Right Now

Key Points Eli Lilly is performing very well as a business right now, which should please shareholders. Novo Nordisk has fallen behind Eli Lilly in the GLP-1...

Contrarian Opinion: Novo Nordisk Is A Better Buy Than Eli Lilly Right Now
Seeking Alpha 2d
France to become first EU nation to cover weight-loss meds

France has become the first EU nation to reimburse weight loss medications, including blockbuster GLP-1s from Novo Nordisk (NVO) and Eli Lilly (LLY), with cover...

France to become first EU nation to cover weight-loss meds
CNBC 2d
CVS to restore coverage of Zepbound, add Eli Lilly's obesity pill to drug plans

An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March 28, 2024. CVS Health on Thursday said it will re...

CVS to restore coverage of Zepbound, add Eli Lilly's obesity pill to drug plans
Simply Wall St 2d
Novo Nordisk Advances Oral Wegovy Lead As Investor Focus Shifts To Uptake

Novo Nordisk (NYSE:NVO) has gained a lead in oral anti obesity pills with its oral Wegovy following a positive opinion from the European Medicines Agency. Earl...

Novo Nordisk Advances Oral Wegovy Lead As Investor Focus Shifts To Uptake
The Motley Fool 3d
Novo Nordisk Is Beating Eli Lilly in the Obesity Pill Market. Should Lilly Investors Be Worried?

Novo Nordisk (NVO +0.89%) pioneered weight loss medicines with Wegovy, an anti-obesity therapy that quickly became a hit. However, it lost its lead to Eli Lilly...

Novo Nordisk Is Beating Eli Lilly in the Obesity Pill Market. Should Lilly Investors Be Worried?

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.